Movano Inc. (MOVE)
| Previous close | 0.3949 |
| Open | 0.4001 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.4000 - 0.4400 |
| 52-week range | 0.3700 - 1.5000 |
| Volume | |
| Avg. volume | 232,625 |
| Market cap | 42.745M |
| Beta (5Y monthly) | 0.21 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireMovano Health Submits Exemplary Sp02 Clinical Trial Results in Key Step Towards FDA 510(k) Clearance Decision
Movano Health (Nasdaq: MOVE) announced that it successfully submitted updated pivotal clinical trial results as well as proof of enhanced medical device usability on April 22, 2024 to the U.S. Food and Drug Administration (FDA) as part of its 510(k) filing for the Company's first commercial medical device, the Evie Med Ring pulse oximeter. An FDA clearance would bring Movano Health a significant step closer in its pursuit to disrupt the wearables industry while unlocking significant partnership
- PR Newswire
Movano Health to Report First Quarter 2024 Financial Results on Wednesday May 15, 2024
Movano Health (Nasdaq: MOVE), a pioneer in health technology, today announced that it will report first quarter 2024 financial and operating results on Wednesday May 15, 2024, after the market close. Management will host a conference call and live audio webcast to discuss these results and provide a business update on the same day at 2:00 pm PT/5:00 pm ET.
- PR Newswire
Movano Health Closes $24 Million Private Placement
Movano Health (Nasdaq: MOVE), a pioneer in health technology, has closed on a $24.1 million private placement, totaling 45.3 million units, with each unit consisting of one share of the Company's common stock (or pre-funded warrant in lieu thereof) and one warrant to purchase a share of common stock, to a select group of investors that includes a tier-one multi-billion dollar medical device company, institutional and accredited investors, and members of the Company's management team and board of
